Technology
Colloid & dispersion platform
Without altering substances chemically, we manage solubility through colloidalization and dispersion: hydrophobic to hydrophilic and back. Stable in storage, functional in use, degraded by design afterward. Our ultimate target is injectables.
BigBasin's technology comes down to colloidalization and dispersion: diagnose a substance's solubility behavior, turn it into a stable colloid without altering the molecule, and aim ultimately at injectable dispersions.
The principle at a glance
01
Aggregated
A poorly soluble molecule clumps together in water and settles out.
02
Encapsulated
A carrier wraps the molecule. The molecule itself is left unchanged.
03
Dispersed
Uniform particles stay dispersed in water and release at a set rate.
The platform in three steps
-
Solubility diagnosis & interface design
We assess a substance's hydrophobicity and hydrophilicity, then design a dispersion strategy.
We evaluate the molecule's lipophilicity, hydrophilicity, surface properties, and aggregation behavior, then design which carrier and interfacial structure will form a stable colloid. The principle is to leave the molecule chemically unchanged.
-
Colloidalization & nanodispersion
We disperse hydrophobic substances stably in water, and implement the reverse direction too.
By combining interfacial agents, carriers, and particle processes, we turn poorly soluble substances into uniform colloids. Biodegradable polymers such as polylactic acid (PLA) are one of the available carriers; we choose materials to fit the goal. Particle size and distribution are controlled through process variables such as nanoprecipitation and solvent evaporation.
-
Stable dispersion & injectable form
We build dispersions that stay stable without aggregation, design release and degradation, and target injectable formulations as the ultimate goal.
Formulations are designed to stay stable through storage and use. With biodegradable carriers, the release rate of the active and the degradation timing of the carrier are treated as design variables too. Ultimately we target injectable forms of poorly soluble drugs dispersed in water without molecular modification, meeting particle-size, stability, and safety requirements step by step.
Why our technology
-
Modification-free dispersion
We bring poorly soluble substances into a stable dispersed state without changing the molecule, stabilizing the active and improving bioavailability without prodrugs or salt formation.
-
Colloidal stability & process control
By controlling interfaces, particle structure, and process variables, we consistently produce stable colloids that resist aggregation, designing storage stability together with release and degradation behavior in use.
-
Material-agnostic, injectable-oriented
We choose among carriers, including biodegradable polymers such as PLA, to fit the goal, with the injectable formulation of poorly soluble drugs as the ultimate target.
Versus existing approaches
| Approach | How it works | What remains |
|---|---|---|
| Prodrug | Chemically attaches a solubilizing group, creating a new compound. | Treated as a new molecule, requiring fresh safety and PK validation. |
| Salt formation | Converts an ionizable molecule into a salt to raise solubility. | Only applies to ionizable molecules, with polymorph and stability issues. |
| Surfactant solubilization | Dissolves the active inside high-concentration surfactant micelles. | Carries a surfactant burden and can re-precipitate on dilution. |
| Colloidal dispersion (BigBasin) | Leaves the molecule intact and builds a stable dispersed state through carrier and interface design. | The difference No molecular modification, so existing safety data stays valid, and biodegradable carriers can be chosen. |
Research & IP
The basis of our technology
BigBasin's colloid and dispersion-stabilization technology is grounded in the founders' intellectual property, peer-reviewed papers, and conference presentations. We disclose the underlying core technology and its track record transparently.
Intellectual property
- Composite particles, and cosmetic ** and dermal-aesthetic injectables
- ** for enhanced bioavailability and sustained release, and their preparation
- **-based microneedle fabrication process
- pH-sensing, photothermal microcapsules and **
Publications (corresponding author)
Conference talks
- 2026.09 Anti-adhesive single-mold microneedle IUPAC-PSK50 (Busan BEXCO) · Session S4 Colloids/Interfaces